TIPE2 suppresses atherosclerosis by exerting a protective effect on macrophages via the inhibition of the Akt signaling pathway

DAN LI¹ and YING TAN²

¹Department of Geriatrics, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011; ²Department of Cardiovascular Medicine, The First Affiliated Hospital of University of South China, Hengyang, Hunan 421000, P.R. China

Received May 2, 2018; Accepted November 30, 2018

DOI: 10.3892/etm.2019.7316

Abstract. Macrophage apoptosis and inflammation serve pivotal roles in the occurrence of atherosclerosis. However, the detailed underlying mechanism of macrophage action during atherosclerosis is poorly understood. Tumor necrosis factor-α-induced protein 8-like 2 (TIPE2) is a well-known negative regulator of the immune response. The current study assessed the association between TIPE2 and apoptosis-associated molecules in macrophages during atherosclerosis, as well as the role of TIPE2 in macrophage inflammation. RAW264.7 macrophages were subsequently transfected with a TIPE2 expression plasmid. Following oxidized low-density lipoprotein (oxLDL) induction (100 µg/ml) for 48 h, macrophage apoptosis was assessed via Annexin V/propidium iodide dual staining. The apoptosis-associated factors and Akt signaling pathway-associated factors were also evaluated via western blot analysis. The expression of inflammatory factors was determined via a reverse transcription-quantitative polymerase chain reaction assay and western blotting. Furthermore, a transwell assay was performed to test cell invasion ability. NF-κB phosphorylation and nuclear translocation were also assessed via western blotting. The results demonstrated that TIPE2 overexpression may promote oxLDL-induced RAW264.7 macrophage apoptosis by inhibiting the protein kinase B (Akt) signaling pathway. Furthermore, it was demonstrated that TIPE2 significantly reduced oxLDL-induced tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6) and monocyte chemoattractant protein 1 expression (MCP-1), and increased IL-10 expression by suppressing NF-κB phosphorylation and nuclear translocation in RAW264.7 macrophages. These results indicated that TIPE2 serves a protective role in oxLDL-induced RAW264.7 macrophages, and its mechanism may partly be exerted via the inhibition of the PI3K/Akt signaling pathway and the reduction of the macrophage inflammatory response achieved via the suppression of NF-κB signal activation.

Introduction

Atherosclerosis is a chronic inflammatory disease of the arterial wall arising from an unbalanced lipid metabolism and a maladaptive inflammatory response (1). Previous evidence has demonstrated that atherosclerosis commonly occurs in the sub-endothelial space (intima) of medium-sized arteries around disturbed blood flow and is induced by an interaction between endothelial dysfunction and sub-endothelial lipoprotein retention (2). Statistical analysis has also revealed that atherosclerosis is a leading cause of mortality, potentially at an early age (3). Hyperlipidemia, monocyte recruitment, differentiation into macrophages, foam cell formation and induced inflammation are key cellular processes that result in atherosclerosis (4). Although its pathogenesis is not fully understood, atherosclerosis is a complex chronic inflammatory disease, in which continuous dyslipidemia and inflammation serve important roles (5). Atherosclerosis-associated inflammation is triggered by certain atherogenic lipid mediators, including oxidized low-density lipoprotein (oxLDL), which is a primary risk factor for the occurrence and development of atherosclerosis (6). Additionally, various types of cytokines release pro-inflammatory and anti-inflammatory factors at all atherosclerotic stages (7,8).

Tumor necrosis factor-α (TNF-α)-inducible protein 8-like 2 (TIPE2) is a novel protein that is crucial for the regulation of immune homeostasis. It shares considerable sequence homology with members of the TNF-α-inducible protein 8 family, which are also known to maintain cellular and immune homeostasis (9,10). It has been demonstrated that murine TIPE2 deficiency contributes to certain inflammatory diseases, including childhood asthma and that the aberrant expression of TIPE2 is associated with various human infectious diseases and autoimmune disorders, including systemic lupus erythematosus, asthma, hepatitis B and stroke (10-13). Furthermore, a previous study has demonstrated that TIPE2 accelerates the differentiation of M2 macrophages by activating the phosphoinositide 3-kinase (PI3K)-protein kinase B

Correspondence to: Dr Ying Tan, Department of Cardiovascular Medicine, The First Affiliated Hospital of University of South China, 6 Chuanshan Road, Hengyang, Hunan 421000, P.R. China
E-mail: yaleixier20022010@163.com

Key words: atherosclerosis, tumor necrosis factor-α-induced protein 8-like 2, macrophage, apoptosis, inflammation, protein kinase B, nuclear factor-κB
(AKT) signaling pathway and may therefore produce important effects during the resolution of inflammation and tissue repair (14). Additionally, it has been revealed that TIPE2 promotes Fas-induced apoptosis by inhibiting the activation of activating protein-1 and nuclear factor-κB (NF-κB) by binding to caspase-8 (9). Although TIPE2 has become a key molecule in the prevention of inflammatory diseases, its mechanism is still unclear. The current study hypothesized that TIPE2 may serve a protective role in atherosclerosis by negatively regulating macrophages and inflammation. A series of in vitro experiments were designed and performed in the present study to confirm this hypothesis.

Materials and methods

Cell culture and grouping. RAW264.7 macrophages obtained from the American Type Culture Collection (Manassas, VA, USA) were cultured in Dulbecco's Modified Eagle's medium (DMEM; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing 10% fetal bovine serum (FBS, Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin/streptomycin at 37°C in a humidified incubator with 5% CO2. The medium was changed once every 1-2 days and the cells at logarithmic growth phase were selected for subsequent experimentation. Cells were inoculated into 6-well plates at a density of 5x10^5 cells/well, with two duplicated wells for each group. According to the manufacturer's protocol, pRK5-mock or pRK5-TIPE2 vectors (Invitrogen; Thermo Fisher Scientific, Inc.) were transfected into RAW264.7 cells using the X-treme GENE HP DNA transfection system (Roche Diagnostics, Basel, Switzerland) and incubated with oxLDL (Anhui Yiyuan Biotechnology Co., Ltd., Anhui Sheng, China) at room temperature for 48 h. Serum-free RNA (5 μg) and transfection solution (μl) was then added in a ratio of 1:3 (provided as part of the X-treme GENE HP DNA kit). Following transfection for 6 h, the original culture medium was replaced with DMEM medium and cells were further incubated for culture at 37°C. Following 48 h, cells were harvested for subsequent experimentation. Cells were then assigned into blank (containing complete medium), oxLDL (100 μg/ml oxLDL), oxLDL + pRK5-mock (100 μg/ml oxLDL with the pRK5 empty vector), and oxLDL + pRK5-TIPE2 (100 μg/ml oxLDL with pRK5-TIPE2 the plasmid) groups.

RNA isolation and quantitation. Total RNA was extracted from cells using the TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.). Reverse transcription was then performed using the M-MLV Reverse Transcription system (Takara Biotechnology Co., Ltd., Dalian, China). The reaction conditions were as follows: 42°C for 2 min, 95°C for 5 sec and 37°C for 15 min. obtained cDNA was subsequently stored at 4°C until further use. RNA samples (1 μg) were selected for quantitative polymerase chain reaction (qPCR) and the obtained complementary DNA was analyzed three times using SYBR Green (Takara Bio, Inc., Otsu, Japan). The ABI7500 quantitative PCR instrument (Applied Biosystems; Thermo Fisher Scientific, Inc.) was utilized for qPCR. The thermocycling conditions were as follows: Pre-denaturation at 95°C for 10 min, denaturation at 95°C for 10 sec, annealing at 60°C for 20 sec and extension at 72°C for 34 sec, with a total of 40 cycles. Relative mRNA concentrations were determined using the 2^-ΔΔCq (15), with Cq representing the mean threshold cycle difference following normalization to β-actin expression. Each experiment was repeated three times. The following primer sequences were utilized: TNF-α forward, 5'-ACCTCTACCTCAGATCATCCTC-3' and reverse, 5'-TGTTGTTT GCTACGAGCT-3'; monocyte chemoattractant protein 1 (MCP-1) forward, 5'-CACAACACA CCTCAAGACT-3' and reverse, 5'-AGGCTACAGTCTCCGAGTCA-3'; interleukin (IL)-6 forward, 5'-AGGCCCTTGAGAAGGAAGCATGTA-3' and reverse, 5'-GAGGTGTATCTCCTGTGAGTCT-3'; IL-10 forward, 5'-TG GCCAGAAATCAAGGACG-3' and reverse, 5'-CACGAGACTCTAATACACACT-3'; β-actin forward, 5'-GGCTGTATTCCTCCCTCATCG-3' and reverse, 5'-CCAGTTGGTAACAATGGCATGT-3'.

Annexin V/propidium iodide (PI) dual staining. Cell apoptosis was detected using the dual staining Annexin V/PI Apoptosis Detection kit (Nanjig Keygen Biotech Co., Ltd., Nanjing, China) under a Cytomics FC500 flow cytometer (Beckman Coulter, Inc., Brea, CA, USA). The percentage of apoptotic cells in each quadrant was calculated using Flow Jo Software version 7.2.2 (FlowJo LLC, Ashland, OR, USA). Each experiment was performed three times.

Transwell inserts assay. Matrigel (30 μl) dissolved overnight and diluted with FBS-free DMEM in triplicate volumes was added to the wells in the upper chamber at 15 min intervals. Each well in the upper chamber was inoculated with 2x10^5 cells. DMEM (0.5 ml) containing 10% FBS was added to each well of the lower chamber. Following incubation at 37°C for 24 h, cells were fixed with 4% paraformaldehyde for 20-30 min at room temperature and stained with 0.1% crystal violet for 30 min at room temperature to remove any uninfected cells from the upper chamber. Subsequently, cells were washed with 0.1 M PBS. Cells were then counted and photographed in randomly selected fields under a light microscope (magnification, ×200). The experiment was repeated three times and the mean value of cells that passed through the Matrigel was analyzed to determine cell invasion.

Protein extraction. Cells were washed with PBS and lysed with radioimmunoprecipitation lysis buffer (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) based on the manufacturer's protocol. Cell supernatants were collected as whole cell lysates following centrifugation at 12,000 x g for 15 min at 4°C. Nuclear and cytoplasmic proteins were extracted using a nuclear and cytoplasmic protein extraction kit (Beyotime Institute of Biotechnology, Haimen, China). Cells were then dissolved with cytoplasmic protein extraction agent A (provided by the protein extraction kit) and incubated for 1 min on ice after vortexing (VWR Digital minivortexer, cat. no. 58816-121; VWR International Ltd., Lutterworth, Leicestershire, UK) at maximum speed for 5 sec. Subsequently, cytoplasmic protein extraction agent B (provided by the protein extraction kit) was added and the cells were incubated on ice for 1 min after vortexing at maximum speed for 10 sec. Samples were centrifuged at 12,000 x g for 5 min at 4°C and the supernatants containing cytoplasmic extracts were collected. A nuclear protein extraction agent (provided in the protein extraction kit)
Western blot analysis. Protein was extracted from cells as aforementioned and separated (50 µg) using 10% SDS-PAGE and transferred to polyvinylidene fluoride membranes (EMD Millipore, Billerica, MA, USA). Following blocking with 5% non-fat milk in TBST for 1 h at room temperature, membranes were incubated with the following specific antibodies at 4°C overnight: Anti-caspase3 (1:500; cat. no. ab4051; Abcam, Cambridge, UK), anti-TNF-α (1:1,000; cat. no. ab90437; Abcam), anti-MCP-1 (1:2,000; cat. no. ab7202; Abcam), anti-IL-6 (1:1,000; cat. no. sc-130326; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), anti-IL-10 (1:2,000; cat. no. ab3483; Abcam), anti-phosphorylated (p)-NF-κB p65 (Ser 536; 1:1,000; cat. no. 3033; Cell Signaling Technology, Inc.), anti-NF-κB p65 (1:1,000; cat. no. 92674; Cell Signaling Technology), anti-p-Akt (1:1,000; cat. no. 38449; Abcam), anti-total(Akt) (1:1,000; cat. no. 179463; Abcam), anti-Histone H3 (1:1,000; cat. no. H0164; Sigma-Aldrich; Merck KGaA) and anti-β-actin (1:1,000; cat. no. 1791; Sigma-Aldrich; Merck KGaA). Membranes were then washed three times TBST (for 10 min each). Horseradish peroxidase (HRP) conjugated rabbit anti-mouse IgG-H&L (cat. no. ab6728; 1:5,000; Abcam) and HRP conjugated goat anti-rabbit IgG-H&L (cat. no. ab6721; 1:5,000; Abcam) against primary antibodies were also added to the membranes and incubated at room temperature. Membranes were washed as aforementioned at room temperature with shaking. An ECL Western blot detection kit (EMD Millipore, Billerica, MA, USA) was used for visualization. Relative protein levels were quantified using ImageJ software version 1.0 (National Institutes of Health, Bethesda, MD, USA).

Statistical analysis. All calculations were performed using SPSS 19.0 (IBM Corp., Armonk, NY, USA) and all experiments were repeated three times, with data being expressed as the mean ± standard deviation. Statistical analysis was performed using a Student’s t-test. P<0.05 was considered to indicate a statistically significant result.

Results

TIPE2 promotes macrophage apoptosis. RAW264.7 macrophages were transfected with the TIPE2 expression plasmid pRK5-TIPE2 (pRK5-TIPE2 group) and the pRK5-mock plasmid (control group). Following transfection for 48 h, TIPE2 expression was detected via reverse transcription (RT)-qPCR and western blotting. The results revealed that TIPE2 mRNA and protein expression were significantly higher than that of the pRK5-mock group (P<0.05). This indicates the successful construction of the TIPE2 overexpression vector.

To verify the effect of TIPE2 on the apoptosis of oxLDL-induced RAW264.7 macrophages, RAW264.7 cells were transfected and stimulated with oxLDL (100 µg/ml) for 48 h. Cell apoptosis was then assessed using an AnnexinV/PI cell apoptosis detection kit. The results demonstrated that compared with the blank group, the oxLDL group exhibited a significantly higher percentage of apoptotic cells (P<0.05). Compared with the oxLDL + mock group, the oxLDL + pRK5-TIPE2 group exhibited a further increase in macrophage apoptosis (P<0.05; Fig. 1C). The activation of caspase-3 was detected via western blotting and the results revealed that the activation of caspase-3 in oxLDL-stimulated macrophages was significantly higher than those of the blank group. Additionally, the activation of macrophage caspase-3 was further enhanced following TIPE2 overexpression (P<0.05; Fig. 1D). The results demonstrated that the overexpression of TIPE2 promotes the apoptosis of oxLDL-induced RAW264.7 macrophages.

TIPE2 inhibits the PI3K/AKT signaling pathway in macrophages. The PI3K/Akt signaling pathway is important for the regulation of apoptosis (16). To assess whether TIPE2 regulates the Akt signaling pathway and to assess the molecular mechanism of macrophage apoptosis as regulated by TIPE2, the activation of Akt was determined via western blot. The results demonstrated that the phosphorylation of Akt in macrophages increased following stimulation with oxLDL (P<0.05; Fig. 2). However, Akt phosphorylation decreased following TIPE2 overexpression (P<0.05; Fig. 2). No significant differences were identified in the level of Akt alone in macrophages. These results indicate that TIPE2 promotes the apoptosis of oxLDL-induced macrophages, which may be associated with the negative regulation of the PI3K/Akt signaling pathway activation.

TIPE2 inhibits the inflammatory response of macrophages. Inflammatory cell infiltration serves a key role in atherosclerosis (17). To verify the effect of TIPE2 on the inflammatory response of oxLDL-induced RAW264.7 macrophages, western blotting and RT-qPCR were performed. The results indicated that when compared with the blank group, oxLDL treated macrophages exhibited a significantly increased mRNA and protein expression of TNF-α, IL-6 and MCP-1. These cells also exhibited a decreased IL-10 expression (P<0.05; Fig. 3). The results indicate that the inflammatory model was successfully constructed. Furthermore, compared with the oxLDL + mock group, the oxLDL + pRK5-TIPE2 group exhibited a decreased expression of TNF-α, IL-6 and MCP-1, and an increased IL-10 expression (P<0.05; Fig. 3).

Inhibition of macrophage migration by TIPE2. The aforementioned results indicate that the overexpression of TIPE2 inhibits the expression of MCP-1. Therefore, a transwell assay was performed to detect changes in the migration of macrophages in each group. When compared with the blank group, the results revealed an increased macrophage migration in the oxLDL group (P<0.05; Fig. 4). Furthermore, compared with the oxLDL + mock group, the oxLDL + pRK5-TIPE2 group inhibited cell migration (P<0.05), which was congruent with the previously mentioned results (Fig. 4).

TIPE2 inhibits the activation of NF-κB in macrophages. NF-κB serves a key role in the inflammatory response of oxLDL-induced macrophages (18). In the current study,
cells were treated with the pRK5-TIPE2 plasmid and with oxLDL (100 µg/ml). The results of western blotting revealed that, when compared with the blank group, oxLDL-treated macrophages exhibited increased levels of NF-κB p65 (S536) phosphorylation (P<0.05). Additionally, the oxLDL + pRK5-TIPE2 group exhibited a reduced phosphorylation of NF-κB p65 (S536; P<0.05; Fig. 5A) compared with the oxLDL + mock group. The current study further assessed the effect of TIPE2 on the nuclear translocation of macrophage NF-κB via western blotting. The results
revealed that, compared with the blank group, the oxLDL group exhibited an increased expression of NF-κB p65 (P<0.05; Fig. 5B). The oxLDL + pRK5-TIPE2 group also presented a decreased NF-κB p65 expression compared with the oxLDL + mock group (P<0.05; Fig. 5B). These results indicate that TIPE2 inhibits the activation of NF-κB in oxLDL-induced macrophages.

**Discussion**

As a chronic inflammatory arterial disease, atherosclerosis is reported to be involved in interplay between various types of cell types and cytokine networks, which may connect several cardiovascular risk factors to the immuno-inflammatory activation of the vascular wall (19). Additionally, macrophages...
are the primary source of foam cells, which serve as indicators of atherosclerotic lesions (20). The present study utilized RAW264.7 cells transfected with a TIPE2-expression plasmid to assess the role of TIPE2 in atherosclerosis. The results of the current study demonstrated that TIPE2 serves a protective role in atherosclerosis via its effect on macrophages.

Macrophages serve vital roles in all stages of atherosclerosis, which may result in heart attacks and strokes (21). The current study revealed that TIPE2 promotes macrophage apoptosis and inhibits the inflammatory response and migration of macrophages. A previous study has indicated that the death and ability of macrophages to clear dead cells are key factors in determining the pathological stage and plaque stability of atherosclerosis (22). It has been demonstrated that activated macrophages produce inflammatory cytokines, proteases, cytotoxic oxygen and nitrogen radical molecules that promote atherosclerosis (23,24). A previous study has also demonstrated that macrophage dysfunction reduces atherosclerosis in apolipoprotein E 2/2 mice (25). Macrophage migration has also been reported to be associated with metastasis (26,27). Furthermore, the migration of macrophages is a primary cause of atherosclerotic plaques (4). TIPE2 also modulates inflammation and carcinogenesis (28). TIPE2 is preferentially expressed in lymphoid tissues, and cells with TIPE2 knockout react strongly to the activation of toll-like receptors (TLR) and T cell receptors (29). Previous evidence has also revealed that TIPE2 inhibits phagocytosis and oxidative stress in macrophages by suppressing Rac GTPases (30). Furthermore, highly expressed TIPE2 in macrophages has been demonstrated to function as a negative regulator of innate immunity via the suppression of TLR signaling (31). A previous study has revealed that oxLDL exhibits a chemotactic effect on monocytes, promoting monocyte differentiation into macrophages, and also induces the release of pro-inflammatory cytokines by binding to cluster of differentiation 36 (32). Furthermore, the expression of TIPE2 in macrophages has been determined to influence the degree of reactive oxygen species generation, which when increased, may trigger inflammatory responses leading to atherogenesis (31). In line with the results of the present study, a previous study also reported that TIPE2 knockout and knockdown macrophages may produce more IL-6 and IL-12 following lipopolysaccharide stimulation (9).

It has been reported that the increased phosphorylation of AKT at Ser/Thr sites is associated with the inhibition of cell apoptosis (33). The expression of NF-κB and its gene cascade may be modulated by the PI3K/Akt signaling pathway, which serves an important role in cell proliferation, apoptosis and inflammation (34). Furthermore, the expression of pro-inflammatory cytokines including IL-6 and TNF-α, are influenced by NF-κB and activator protein-1 activities (35). The present study confirmed that TIPE2 inhibits the AKT signaling pathway and NF-κB activation in macrophages. It has been demonstrated that activated macrophages trigger the innate immune response and that the AKT pathway gathers inflammation and metabolic signals to modulate this response (36). NF-κB is a key factor in tumorigenesis and development, which serves a unique role in the regulation of tumor macrophage and tumor cell function (37). Additionally, NF-κB in macrophages not only induces inflammation but also promotes the activation of pro-inflammatory genes,
including those of interferon-γ, and during the resolution of inflammation, NF-κB preferentially promotes the activation of anti-inflammatory genes such as IL-10, inducing macrophage apoptosis (38). The movement of NF-κB into the nucleus also promotes the transcription of corresponding pro-inflammatory genes such as TNF-α and IL-1 (39). As a negative regulator of immunity, TIPE2 deficiency contributes to the hyperactivation of the PI3K-Rac pathway as demonstrated by increased AKT, Rac, P21-activated kinase and interferon regulatory factor 3 (40). Consistent with the results of the current study, Zhang et al (41) demonstrated that TIPE2 inhibits the phosphorylation of AKT. Furthermore, previous evidence has revealed that the elevated phosphorylation of c-Jun N-terminal kinase 1/2 (JNK1/2), p38 and inhibitory kappa B in TIPE2-deficient macrophages induced by ox-LDL, indicating that TIPE2 alleviates atherosclerosis by negatively regulating the JNK1/2, NF-κB and p38 pathways (31).

In conclusion, the present study revealed that TIPE2 may serve a negative role in atherosclerosis by promoting macrophage apoptosis and inhibiting the macrophage inflammatory response via the negative regulation of the Akt signaling pathway and NF-κB. These results may not only advance our understanding of the mechanisms utilized by macrophages during atherosclerosis but also may lead to the development of TIPE2-based treatment strategies.

Acknowledgments

Not applicable.

Funding

The current study was supported by grants from the Hunan Health Planning Commission Fund (grant no. 20180200) and Hunan Provincial Natural Science Fund of China (grant no. 13J6092).

Availability of data and materials

All the data generated or analyzed during this study are included in this published article.

Authors' contributions

DL and YT conceived and designed the experiments of the current study. DL analyzed the data: DL. YT and DL contributed reagents/materials/analysis tools and wrote the manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Viola J and Soehnlein O: Atherosclerosis-A matter of unresolved inflammation. Semin Immunol 27: 184-193, 2015.
2. Tabas I, García-Cardelana G and Owens GK: Recent insights into the cellular biology of atherosclerosis. J Cell Biol 209: 13-22, 2015.
3. Libby P, Ridker PM and Hansson GK: Progress and challenges in translating the biology of atherosclerosis. Nature 473: 317-325, 2011.
4. Gui T, Shimokado A, Sun Y, Akasaka T and Muragaki Y: Diverse roles of macrophages in atherosclerosis: From inflammatory biology to biomarker discovery. Mediators Inflamm 2012: 693083, 2012.
5. Wang Y, Han Z, Fan Y, Zhang J, Chen K, Gao L, Zeng H, Cao J and Wang C: MicroRNA-9 inhibits NLRR3 inflammasome activation in human atherosclerosis inflammation cell models through the JAK1/STAT signaling pathway. Cell Physiol Biochem 41: 1555-1571, 2017.
6. Zhang E and Wu Y: MicroRNAs: Important modulators of oxLDL-mediated signaling in atherosclerosis. J Atheroscler Thromb 20: 215-227, 2013.
7. Wang H and Eitzman DT: Acute myocardial infarction leads to acceleration of atherosclerosis. Atherosclerosis 229: 18-22, 2013.
8. Libby P: Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 32: 2045-2051, 2012.
9. Sun H, Gong S, Carmody RJ, Hilliard A, Li L, Sun J, Kong L, Xu L, Hilliard B, Hu S, et al: TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. Cell 133: 415-426, 2008.
10. Xi W, Hu Y, Liu Y, Zhang J, Wang L, Lou Y, Qu Z, Cui J, Zhang G, Liang X, et al: Roles of TIPE2 in hepatitis B virus-induced hepatic inflammation in humans and mice. Mol Immunol 48: 1203-1208, 2011.
11. Li F, Zhu X, Yang Y, Huang L and Xu J: TIPE2 alleviates systemic lupus erythematosus through regulating macrophage polarization. Cell Physiol Biochem 38: 330-339, 2016.
12. Ma Y, Liu X, Wei Z, Wang X, Wang Z, Zhong W, Li Y, Zhu F, Guo C, Zhang L and Wang X: The expression and significance of TIPE2 in peripheral blood mononuclear cells from asthmatic children. Scand J Immunol 78: 523-528, 2013.
13. Zhang Y, Wei X, Liu L, Liu S, Wang Z, Zhang B, Fan B, Yang F, Huang S, Jiang F, et al: TIPE2, a novel regulator of immunity, protects against experimental stroke. J Biol Chem 287: 32546-32555, 2012.
14. Liu R, Fan T, Geng W, Chen YH, Ruan Q and Zhang C: Negative immune regulator TIPE2 promotes M2 macrophage differentiation via the activation of PI3K-AKT signaling pathway. PLoS One 12: e0170666, 2017.
15. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
16. Folko MY, Manzoli L, Poli A, McCubrey JA and Cocco L: PLC and PI3K/Akt/mTOR signalling in disease and cancer. Adv Biol Regul 57: 10-16, 2015.
17. Liu YC, Zou XB, Chai YF and Yao YM: Macrophage polarization in inflammatory diseases. Int J Biol Sci 10: 520-529, 2014.
18. Wang Y, Wang GZ, Rabinovitch PS and Tabas I: Macrophage mitochondrial oxidative stress promotes atherosclerosis and nuclear factor-kB-mediated inflammation in macrophages. Circ Res 114: 421-433, 2014.
19. Taleb S, Tedgui A and Mallat Z: IL-17 and TH17 cells in atherosclerosis: Subtle and contextual roles. Arterioscler Thromb Vasc Biol 35: 258-264, 2015.
20. Shao BZ, Han BZ, Zeng YX, Su DF and Liu C: The roles of macrophage autophagy in atherosclerosis. Acta Pharmacol Sin 37: 150-156, 2016.
21. Tabas I and Bornfeldt KE: Macrophage phenotype and function in different stages of atherosclerosis. Circ Res 118: 653-667, 2016.
22. Linton MF, Babaev VR, Huang J, Linton EF, Tao H and Yang PY: Macrophage apoptosis and efferocytosis in the pathogenesis of atherosclerosis. Circ J 80: 2259-2268, 2016.
23. Afkari E, Balenga NA, Luschning-Schratil P, Wolinski H, Povoden S, Chandak PG, Bogner-Strauss JG, Eder S, Konya V, Kohlwied SD, et al: Impaired Rho GTPase activation abrogates cell polarization and migration in macrophages with defective lipolysis. Cell Mol Life Sci 68: 3933-3947, 2011.
24. Martinez FO, Sica A, Mantovani A and Locati M: Macrophage activation and polarization. Front Biosci 13: 453-461, 2008.
25. Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J and Miyata M: Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci USA 92: 8264-8268, 1995.

26. Green CE, Liu T, Montel V, Hsiao G, Lester RD, Subramaniam S, Goniais SL and Klemke RL: Chemotactrant signaling between tumor cells and macrophages regulates cancer cell migration, metastasis and neovascularization. PLoS One 4: e6713, 2009.

27. Mantovani A and Sica A: Macrophages, innate immunity and cancer: Balance, tolerance, and diversity. Curr Opin Immunol 22: 231-237, 2010.

28. Hao C, Zhang N, Geng M, Ren Q, Li Y, Wang Y, Chen YH and Liu S: Clinical significance of tipe2 protein upregulation in non-Hodgkin's Lymphoma. J Histochem Cytochem 64: 556-564, 2016.

29. Garcia JA, Ferreira HL, Vieira FV, Gameiro R, Andrade AL, Eugênio FR, Flores EF and Cardoso TC: Tumour necrosis factor-alpha-induced protein 8 (TNFAIP8) expression associated with cell survival and death in cancer cell lines infected with canine distemper virus. Vet Comp Oncol 15: 336-344, 2017.

30. Wang Z, Fayngerts S, Wang P, Sun H, Johnson DS, Ruan Q, Guo W and Chen YH: TPE2 protein serves as a negative regulator of phagocytosis and oxidative burst during infection. Proc Natl Acad Sci USA 109: 15413-15418, 2012.

31. Lou Y, Liu S, Zhang C, Zhang G, Li J, Ni M, An G, Dong M, Liu X, Zhu F, et al.: Enhanced atherosclerosis in TIPE2-deficient mice is associated with increased macrophage responses to oxidized low-density lipoprotein. J Immunol 191: 4849-4857, 2013.

32. Janabi M, Yamashita S, Hirano K, Sakai N, Hiraoka H, Matsumoto K, Zhang Z, Nozaki S and Matsuzawa Y: Oxidized LDL-induced NF-kappa B activation and subsequent expression of proinflammatory genes are defective in monocyte-derived macrophages from CD36-deficient patients. Arterioscler Thromb Vasc Biol 20: 1953-1960, 2000.

33. Zhang M, Liu J, Li M, Zhang S, Lu Y, Liang Y, Zhao K and Li Y: Insulin-like growth factor I/insulin-like growth factor I receptor signaling protects against cell apoptosis through the P38/PI3K/AKT pathway in glioblastoma cells. Exp Ther Med 16: 1477-1482, 2018.

34. Liu S, Shen H, Xu M, Liu O, Zhao L, Liu S, Guo Z and Du J: FRP inhibits ox-LDL-induced endothelial cell apoptosis through an Akt-NF-{kappa}B-Bcl-2 pathway and inhibits endothelial cell apoptosis in an apoE-knockout mouse model. Am J Physiol Endocrinol Metab 299: E351-E363, 2010.

35. Yodkoneree S, Ooppachai C, Pomplimon W and Limtrakul Dejkiengkraikul P: O-methylbulbocapnine and dicentrine suppress LPS-induced inflammatory response by blocking NF-{kappa}B and AP-1 activation through inhibiting MAPKs and Akt signaling in RAW264.7 macrophages. Biol Pharm Bull 41: 1219-1227, 2018.

36. Vergadi E, Ieronymaki E, Lyroni K, Vaporidi K and Tsatsanis C: Akt signaling pathway in macrophage activation and M1/M2 polarization. J Immunol 198: 1006-1014, 2017.

37. Biswas SK and Lewis CE: NF-{kappa}B as a central regulator of macrophage function in tumors. J Leukoc Biol 88: 877-884, 2010.

38. Timmer AM and Nizet V: IKKbeta/NF-kappaB and the miscreant macrophage. J Exp Med 205: 1255-1259, 2008.

39. Bonizzi G and Karin M: The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25: 280-288, 2004.

40. Sun H, Zhuang G, Chai L, Wang Z, Johnson D, Ma Y and Chen YH: TIPE2 controls innate immunity to RNA by targeting the phosphatidylinositol 3-kinase-Rac pathway. J Immunol 189: 2768-2773, 2012.

41. Zhang Z, Liu L, Liu C, Cao S, Zhu Y and Mei Q: TIPE2 suppresses the tumorigenesis, growth and metastasis of breast cancer via inhibition of the AKT and p38 signaling pathways. Oncol Rep 36: 3311-3316, 2016.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.